We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Fibrocell (FCSC) Q1 Earnings: What's in Store for the Stock?
Read MoreHide Full Article
Fibrocell Science, Inc. will report first-quarter 2019 earnings results.
The company’s performance over the last four quarters has been encouraging so far with its earnings having surpassed expectations twice while missing the same once. The average trailing four-quarter positive surprise over the last four quarters is 28.30%.
Shares of Fibrocell have soared 64% so far this year, outperforming the industry’s increase of 5%.
Let’s see, how things are shaping up for this announcement.
Factors to Consider
Fibrocell does not have any approved product in its portfolio at the moment. As a result, the company is yet to generate any revenues.
Fibrocell is developing its gene therapy candidate, FCX-007, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a rare, genetic skin disorder. Currently, there are no approved treatments for RDEB.
The company is also developing FCX-007 in collaboration with Intrexon Corporation under its exclusive channel collaboration. The candidate has been granted an Orphan Drug Designation, Rare Pediatric Disease Designation and the Fast Track Designation by the FDA.
Earlier this month, Fibrocell completed a collaboration agreement with New Jersey-based, privately held Castle Creek Pharmaceuticals to develop/commercialize FCX-007. Shares of the company rallied significantly following this move. Moreover, last month, the FDA provided guidance on the design aspects of Fibrocell’s proposed phase III study on FCX-007, named DEFI-RDEB, at a Type-B meeting. The company expects to initiate this evaluation in second-quarter 2019.
We expect management to provide an update on the same on the upcoming investors call.
Fibrocell’s another clinical candidate, FCX-013, is being developed for the treatment of moderate to severe localized scleroderma. The company is currently enrolling in the phase I portion of a phase I/II program on FCX-013 and expects to complete the task in the third quarter of 2019.
Earnings Whispers
The proven Zacks model does not conclusively show that Fibrocell is likely to beat estimates this to-be-reported quarter. This is because a stock needs to have both a positive Earnings ESP and a top Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. But that is not the case here as you will see below.
Earnings ESP: Fibrocell has an Earnings ESP of 0.00%. This is because both the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at a loss of 33 cents each. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Fibrocell currently sports a Zacks Rank of 1, which increases the predictive power of ESP. However, the company’s 0.00% ESP in the combination makes surprise prediction difficult for the stock this reporting cycle.
We caution against Sell-rated stocks (#4 or 5) going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Gilead Sciences, Inc. (GILD - Free Report) has a Zacks Rank of 2 and an Earnings ESP of +1.54%. The company is scheduled to release first-quarter results on May 2, after the market closes.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
Image: Bigstock
Fibrocell (FCSC) Q1 Earnings: What's in Store for the Stock?
Fibrocell Science, Inc. will report first-quarter 2019 earnings results.
The company’s performance over the last four quarters has been encouraging so far with its earnings having surpassed expectations twice while missing the same once. The average trailing four-quarter positive surprise over the last four quarters is 28.30%.
Shares of Fibrocell have soared 64% so far this year, outperforming the industry’s increase of 5%.
Let’s see, how things are shaping up for this announcement.
Factors to Consider
Fibrocell does not have any approved product in its portfolio at the moment. As a result, the company is yet to generate any revenues.
Fibrocell is developing its gene therapy candidate, FCX-007, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a rare, genetic skin disorder. Currently, there are no approved treatments for RDEB.
The company is also developing FCX-007 in collaboration with Intrexon Corporation under its exclusive channel collaboration. The candidate has been granted an Orphan Drug Designation, Rare Pediatric Disease Designation and the Fast Track Designation by the FDA.
Earlier this month, Fibrocell completed a collaboration agreement with New Jersey-based, privately held Castle Creek Pharmaceuticals to develop/commercialize FCX-007. Shares of the company rallied significantly following this move. Moreover, last month, the FDA provided guidance on the design aspects of Fibrocell’s proposed phase III study on FCX-007, named DEFI-RDEB, at a Type-B meeting. The company expects to initiate this evaluation in second-quarter 2019.
We expect management to provide an update on the same on the upcoming investors call.
Fibrocell’s another clinical candidate, FCX-013, is being developed for the treatment of moderate to severe localized scleroderma. The company is currently enrolling in the phase I portion of a phase I/II program on FCX-013 and expects to complete the task in the third quarter of 2019.
Earnings Whispers
The proven Zacks model does not conclusively show that Fibrocell is likely to beat estimates this to-be-reported quarter. This is because a stock needs to have both a positive Earnings ESP and a top Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen. But that is not the case here as you will see below.
Earnings ESP: Fibrocell has an Earnings ESP of 0.00%. This is because both the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at a loss of 33 cents each. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Fibrocell currently sports a Zacks Rank of 1, which increases the predictive power of ESP. However, the company’s 0.00% ESP in the combination makes surprise prediction difficult for the stock this reporting cycle.
We caution against Sell-rated stocks (#4 or 5) going into an earnings announcement, especially when the company is seeing negative estimate revisions.
Fibrocell Science Inc Price and EPS Surprise
Fibrocell Science Inc Price and EPS Surprise | Fibrocell Science Inc Quote
Stocks That Warrant a Look
Here are a few health care stocks worth considering as our model shows that these have the right mix of elements to beat estimates this time around.
Aduro Biotech, Inc. has a Zacks Rank #2 and an Earnings ESP of +82.00%. You can see the complete list of today’s Zacks #1 Rank stocks here.
Gilead Sciences, Inc. (GILD - Free Report) has a Zacks Rank of 2 and an Earnings ESP of +1.54%. The company is scheduled to release first-quarter results on May 2, after the market closes.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>